

Lesotho Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Lesotho			
2. Grant number: 17-LSO-12c-X / /			
3. Date of Decision Letter: 19 December 2016			
4. Date of the Partnership Framework Agreement: 30 November 2012			
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID			
8. Programme duration¹: 2014 -2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2014-2016	2017	Total ²
Programme Budget (US\$)	1,124,005 ³	598,500	1,722,505
10. Vaccine introduction grant (in US\$): . Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2014-2016	2017	
Number of Pneumococcal vaccines doses		158,900	
Annual Amounts (US\$)	1,124,005 ⁵	598,500	

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.													
13. Self-procurement: Not applicable													
<p>14. Co-financing obligations: Reference code: 17-LSO-12c-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2017</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>16,000</td> </tr> <tr> <td>Number of AD syringes</td> <td>16,900</td> </tr> <tr> <td>Number of safety boxes</td> <td>200</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$52,585</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>US\$56,000</td> </tr> </tbody> </table>		Type of supplies to be purchased with Country funds in each year	2017	Number of vaccine doses	16,000	Number of AD syringes	16,900	Number of safety boxes	200	Value of vaccine doses (US\$)	US\$52,585	Total co-financing payments (US\$) (including freight)	US\$56,000
Type of supplies to be purchased with Country funds in each year	2017												
Number of vaccine doses	16,000												
Number of AD syringes	16,900												
Number of safety boxes	200												
Value of vaccine doses (US\$)	US\$52,585												
Total co-financing payments (US\$) (including freight)	US\$56,000												
15. Operational support for campaigns: Not applicable													
16. Additional reporting requirements: Not applicable													
<table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>May</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>	Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat							
Reports and other information	Due dates												
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May												
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat												
<p>17. Financial clarifications: Not applicable</p> <p><i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>													
18. Other conditions: Not applicable													

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

16 December 2016